Xagena.net - Update in Medicine

FDA has authorised Pfizer and BioNTech's Covid-19 vaccine for emergency use

The U.S. Food and Drug Administration ( FDA ) has issued the first emergency use authorization ( EUA ) for a vaccine for the prevention of coronavirus disease 2019 ( COVID-19 ) caused by severe acute ... read article

MHRA: Managing allergic reactions following COVID-19 vaccination with the Pfizer / BioNTech vaccine

MHRA [ The Medicines and Healthcare products Regulatory Agency ] ( 9 December 2020 ) has issued updated guidance to COVID-19 vaccination centres about the management of anaphylaxis, following two repo ... read article

Primary efficacy analysis of the phase 3 COVE study of mRNA-1273 involving 30,000 participants has included 196 cases of COVID-19, of which 30 cases were severe

Moderna, a biotechnology company pioneering messenger RNA ( mRNA ) therapeutics and vaccines to create a new generation of transformative medicines for patients, has announced that the primary effica ... read article

AZD1222 vaccine has met primary efficacy endpoint in preventing COVID-19

Results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil have shown the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or ... read article

Phase 3 study of covid-19 vaccine candidate, BNT162b2, has met all primary efficacy endpoints

Pfizer and BioNTech have announced that, after conducting the final efficacy analysis in their ongoing phase 3 study, the mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primar ... read article

mRNA-1273, a COVID-19 vaccine candidate, has met primary efficacy endpoint in the first interim analysis of the phase 3 COVE study

Moderna has announced that the independent, NIH-appointed Data Safety Monitoring Board ( DSMB ) for the phase 3 study of mRNA-1273, a vaccine candidate against COVID-19, has informed Moderna that the ... read article

BNT162b2, vaccine candidate is more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis

According to Pfizer and BioNTech, mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 ... read article

Clinical trial data on Bamlanivimab and Etesevimab, two SARS-CoV-2 neutralizing antibodies

Data from a new interim analysis of the BLAZE-1 clinical trial has shown that combination therapy with two SARS-CoV-2 neutralizing antibodies has reduced viral load, symptoms and COVID-related hospita ... read article

ACTT-2 trial: Baricitinib has significant effect on recovery time in COVID-19 patients requiring Oxygen

Baricitinib in combination with Remdesivir has reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection compared with Remdesivir. This finding was part of additio ... read article

RECOVERY trial: Dexamethasone reduces COVID-19 patient deaths by one-third

A trial launched in March 2020 has released its results, finding that Dexamethasone reduced deaths of ventilated COVID-19 patients by one-third. The RECOVERY trial was established as a randomised c ... read article

FDA has approved clinical trial for Tocilizumab to treat hospitalized patients with severe COVID-19 pneumonia

The FDA ( U.S. Food & Drug Administration ) has approved a randomized, double-blind, placebo-controlled phase III clinical trial in collaboration with BARDA ( Biomedical Advanced Research and Deve ... read article

COVID-19: early positive results for BNT162b1, a vaccine against SARS-CoV-2-receptor binding domain

Initial data from ongoing German phase 1/2, open-label, non-randomized, non-placebo-controlled, dose-escalation trial, that is part of the global mRNA-based vaccine program against SARS-CoV-2, were pr ... read article

COVID-19 pandemic has increased out-of-hospital cardiac arrest cases and deaths in New York City

The COVID-19 pandemic in New York City caused a surge in out-of-hospital cardiac arrests and deaths, according to a study co-authored by researchers at Albert Einstein College of Medicine, Montefiore ... read article

The first, comprehensive immunological model of COVID-19

The natural history of COVID-19 caused by SARS-CoV-2 is extremely variable, ranging from asymptomatic infection, to pneumonia, and to complications eventually fatal. Researchers have proposed the ... read article